Brain Cancer Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | Medicenna, Servier, Genentech, Merck, Daiichi Sankyo, Bayer, MedImmune, Immunomic

Brain Cancer Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - Estimates DelveInsight | Medicenna, Servier, Genentech, Merck, Daiichi Sankyo, Bayer, MedImmune, Immunomic
Delveinsight Business Research LLP
As per DelveInsight, the Brain Cancer Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Brain Cancer and the launch of new therapies in the market.

DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Brain Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Brain Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Brain Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Brain Cancer: An Overview

A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases that have in common the abnormal development of mass lesions in the brain, spinal cord, or its coverings. A brain tumor can be classified into two main groups, i.e., primary and metastatic.

A primary brain tumor is often described as “low grade” or “high grade.” A low-grade tumor generally grows slowly, but it can turn into a high-grade tumor, whereas a high-grade tumor is more likely to grow faster. Secondary brain tumors, also called brain metastases, are much more common than primary tumors in adults.

Primary brain tumors originate in the brain itself or tissues close to it, such as in the brain-covering membranes (meninges), cranial nerves, pituitary gland, or pineal gland. Brain cancer cells may travel short distances within the brain, but generally do not spread beyond the brain. Primary tumors are categorized as glial (composed of glial cells) or non-glial (developed on or in the brain’s structures, including nerves, blood vessels, and glands). They can also be divided into malignant or benign tumors. 

The most common types of primary tumors in adults are meningiomas and astrocytomas, such as glioblastoma multiforme (GBM). In children, the most common types of brain tumors include medulloblastomas, low-grade astrocytomas (pilocytic), ependymomas, craniopharyngiomas, and brainstem gliomas.

Brain Cancer Market Key Facts

  • The Brain Tumor market size in the seven major markets was estimated to be USD 2,089.4 Million in 2020.

  • The United States accounts for the largest market size of USD 986.0 Million in 2020 compared to EU5 (Italy, Germany, France, Spain, and the UK) and Japan, respectively.

  • Among the EU5 countries, Italy had the highest market size with USD 214.4 Million in 2020, while the United Kingdom had the lowest market size with USD 129.8 Million in 2020.

  • The Japan Brain Tumors market accounted for USD 256.7 Million in 2020.

  • The total incident population of Primary Brain Tumors in the 7 major markets was estimated to be 60,100+ in 2020. In the case of Primary Brain Tumors patients in the United States, the incident cases were 23,000+ in 2020.

  • In the United States, the incidence of Brain Tumors was 13,500+ in males and 9,500+ in females, in 2020.

  • In the EU5 countries, the incident population of Primary Brain Tumors was maximum in Italy with 7,300+ cases, followed by Germany with 7,100+ cases in 2020. While the United Kingdom accounted for the lowest incident population of the indication with 4,400+ cases in 2020.

  • Japan had 8,100+ incident cases of Primary Brain Tumors in 2020.

Brain Cancer Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Brain Cancer pipeline therapies. It also thoroughly assesses the Brain Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Brain Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Brain Cancer Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Brain Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Brain Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Brain Cancer Epidemiology, Segmented as –

  • Total Incidence of Primary Brain Tumors

  • Grade-specific Incidence of Brain Tumors

  • Type-specific Incidence of Brain Tumors

  • Gender-specific Incidence of Brain Tumors

  • Age-specific Incidence of Brain Tumors

Brain Cancer Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Brain Cancer market or expected to be launched during the study period. The analysis covers the Brain Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Brain Cancer drugs based on their sale and market share.

The report also covers the Brain Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Brain Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Brain Cancer Market Will Evolve and Grow by 2032 @

Brain Cancer Therapeutics Analysis

Treatment options for brain cancers include surgery, radiation therapy, chemotherapy, and targeted therapy. The treatment options and recommendations depend on several factors like the size, type, and grade of the tumor, whether the tumor is putting pressure on vital parts of the brain if the tumor has spread to other parts of the CNS or the body, the possible side effects and finally, the treatment preferences and overall health of the patient.

GBM is not curable and approved treatment options are limited. The tumor is characterized by a high recurrence rate and poor patient prognosis. For these reasons, there is an urgent need for new and efficient treatments such as immunotherapy, gene therapy, and more specific targeted therapies, which will extend the progression-free OS of the patients. Several key players such as Eisai, Medicenna Therapeutics, Immunomic Therapeutics, Bayer, and others are undergoing different clinical trials for brain tumors such as GBM, and others.

Brain Cancer Companies Actively Working in the Therapeutics Market Include

Some of the key companies in the Brain Cancer market include Orbus Therapeutics, Kazia Therapeutics, Bayer, MedImmune, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Servier, Genentech, Merck, Arbor Pharmaceuticals, Daiichi Sankyo, and others.

Emerging and Marketed Brain Cancer Therapies Covered in the Report Include:

Some of the major Brain Cancer Therapies in various states of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), Eflornithine (Orbus Therapeutics) and Regorafenib (Bayer), Durvalumab (MEDI4736; MedImmune), Tasadenoturev (DNX-2401; DNAtrix), ONC201 (Oncoceutics), Selinexor (KPT-330; Karyopharm Therapeutics), VBI-1901 (VBI Vaccines), Paxalisib (GDC-0084; Kazia Therapeutics), AV-GBM-1 (Aivita Biomedical), MDNA55 (Medicenna Therapeutics), VAL-083 (Dianhydrogalactitol; DelMar Pharmaceuticals), ITI-1000 (pp65 DC Vaccine; Immunomic Therapeutics), Everolimus (Novartis), Ad-RTS-hIL-12 in combination with Veledimex (Ziopharm) and INO-5401 + INO-9012 + Cemiplimab (REGN2810; Inovio Pharmaceuticals), and several others.

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Brain Cancer Competitive Intelligence Analysis

4. Brain Cancer Market Overview at a Glance

5. Brain Cancer Disease Background and Overview

6. Brain Cancer Patient Journey

7. Brain Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Brain Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Brain Cancer Unmet Needs

10. Key Endpoints of Brain Cancer Treatment

11. Brain Cancer Marketed Therapies

12. Brain Cancer Emerging Drugs and Latest Therapeutic Advances

13. Brain Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Brain Cancer Market Outlook (In US, EU5, and Japan)

16. Brain Cancer Companies Active in the Market

17. Brain Cancer Access and Reimbursement Overview

18. KOL Views on the Brain Cancer Market

19. Brain Cancer Market Drivers

20. Brain Cancer Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market

“Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Recurrent Head And Neck Cancer Squamous Cell Carcinoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States